Product Images Norethindrone Acetate And Ethinyl Estradiol

This text provides information on studies related to the risk of breast cancer associated with ever and current use of combined oral contraceptives. The studies include the NICHD Women's Contraceptive Study, French E3N cohort Study, Shangai Womens Health Study, Nurses' Health Study II, and Oxford Family Planning Association Study. The Danish Sex Hormone Register Study conducted in 2017 also provides current use data. The Effect Estimate for the studies is given in terms of OR/RR. No additional information is available.*

This text describes different methods of birth control and the frequency of pregnancies for different groups of women based on their contraceptive methods. The methods mentioned include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, no sex during the most fertile days of the monthly cycle, spermicide, and withdrawal. The text also indicates the range of pregnancies per 100 women in one year when using these methods, with the lowest number for contraceptives such as implants, injections, and sterilization, and the highest number for no birth control.*

This is a description of a contraceptive medication containing Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/20 meg and Ferrous Fumarate Tablets, 75 mg. The medication provides a 28-day regimen with 24 days of active therapy and includes 3 dispensers containing 28 tablets each. Each dispenser has a blister card with 24 active tablets and 4 brown tablets. The usual daily dosage must be taken for 28 days. The medication helps prevent pregnancy, but it does not protect against HIV and other sexually transmitted diseases. The medication should be stored between 20-25°C and kept away from children. This medication is manufactured by Amneal Pharmaceuticals in Bridgewater, NJ.*